|
A retrospective three-year analysis using real-world data on uptake of broad-based NextGen sequencing panels in community oncology practices. |
| |
|
Employment - Illumina; IntegraConnect |
Stock and Other Ownership Interests - Illumina; IntegraConnect |
Consulting or Advisory Role - Bristol-Myers Squibb |
Patents, Royalties, Other Intellectual Property - Patent title: Systems and methods for outlier significance assessment Patent date Filed: Nov 3, 2016 IP-1417-PRV; Patent title: Systems and methods for outlier significance assessment Patent date Filed: Nov 3, 2016 IP-1417-PRV |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
| |
|
Employment - IntegraConnect |
| |
|
Employment - IntegraConnect |
| |
|
No Relationships to Disclose |
| |
|
Employment - IntegraConnect |
| |
|
Employment - IntegraConnect |
Consulting or Advisory Role - IntegraConnect |
| |
|
Employment - IntegraConnect |
| |
|
Employment - IntegraConnect |
| |
|
Employment - IntegraConnect |
Stock and Other Ownership Interests - Achieve Life Sciences; Brickell Biotech; Deep 6 AI; Juno Therapeutics; Kite, a Gilead company; Lilly; SABRA Health REIT |
| |
|
Consulting or Advisory Role - Celgene; Celgene |
Travel, Accommodations, Expenses - Celgene |
| |
|
Employment - IntegraConnect |
Stock and Other Ownership Interests - IntegraConnect |